IDH1 and central nervous system cancer: Survival analysis using the CGGA database indicated that patients with low miR-139-5p expression had a worse prognosis than those with high expression in gliomas with wild-type IDH status or mutant IDH status (Fig. 1D, E), and in both primary and recurrent gliomas (Fig. S1E).